ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Phase III COMPASS study with Bayer's rivaroxaban (Xarelto®) shows overwhelming efficacy and meets pr
February 15, 2017Bayer AG and its cooperation partner Janssen Research & Development, LLC have announced that the Phase III trial COMPASS evaluating the efficacy and safety of rivaroxaban (Xarelto®) for the prevention of major adverse cardiac events (MACE)... -
Amgen's Repatha significantly reduced the risk of cardiovascular events in FOURIER outcomes study
February 08, 2017Landmark Repatha cardiovascular outcomes study meets primary and key secondary endpoint. -
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underly
January 09, 2017Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments... -
FDA to review 3 new diabetes drugs that reduce cardiovascular death risk
January 06, 2017The US Food and Drug Administration (FDA) approved supplemental new drug applications for three type 2 diabetes medicines within the empagliflozin family to include data from the empa-red outcome trial.
Pharma Sources Insight January 2025
